Literature DB >> 2583270

Alkaloid homoharringtonine inhibits polypeptide chain elongation on human ribosomes on the step of peptide bond formation.

R M Tujebajeva1, D M Graifer, G G Karpova, N A Ajtkhozhina.   

Abstract

The aim of the present study was to investigate homoharringtonine alkaloid effect on: (i) the nonenzymatic and eEF-1-dependent Phe-tRNAPhe binding to poly(U)-programmed human placenta 80 S ribosomes; (ii) diphenylalanine synthesis accompanying nonenzymatic Phe-tRNAPhe binding; and (iii) acetylphenylalanyl-puromycin formation. Neither nonenzymatic nor eEF-1-dependent Phe-tRNAPhe binding were noticeably affected by the alkaloid, whereas diphenylalanine synthesis and puromycin reaction were strongly inhibited by homoharringtonine. It has been proposed that the site of homoharringtonine binding on 80 S ribosomes should overlap or coincide with the acceptor site of the ribosome.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2583270     DOI: 10.1016/0014-5793(89)81546-7

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  26 in total

1.  Effect of Homoharringtonine on corneal haze after excimer laser photorefractive keratectomy in rabbits.

Authors:  Mingchang Zhang; Li Wang; Yong Wang; Zhengping Ding; Caikeng Mai; Shaosong Nie; Fei Chen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2005

Review 2.  Targeting Translation of mRNA as a Therapeutic Strategy in Cancer.

Authors:  Ipsita Pal; Maryam Safari; Marko Jovanovic; Susan E Bates; Changchun Deng
Journal:  Curr Hematol Malig Rep       Date:  2019-08       Impact factor: 3.952

3.  Omacetaxine mepesuccinate for patients with accelerated phase chronic myeloid leukemia with resistance or intolerance to two or more tyrosine kinase inhibitors.

Authors:  Franck E Nicolini; H Jean Khoury; Luke Akard; Delphine Rea; Hagop Kantarjian; Michele Baccarani; Janis Leonoudakis; Adam Craig; Annie-Claude Benichou; Jorge Cortes
Journal:  Haematologica       Date:  2013-06-10       Impact factor: 9.941

4.  Homoharringtonine contributes to imatinib sensitivity by blocking the EphB4/RhoA pathway in chronic myeloid leukemia cell lines.

Authors:  Bin-Tao Huang; Qing-Chun Zeng; Wei-Hong Zhao; Yan Tan
Journal:  Med Oncol       Date:  2014-01-11       Impact factor: 3.064

5.  Efficacy and safety of homoharringtonine plus cytarabine and aclarubicin for patients with myelodysplastic syndrome-RAEB.

Authors:  Feng Xiao; Ying Li; Weilai Xu; Liangshun You; Chunmei Yang; Hui Liu; Wenbin Qian
Journal:  Oncol Lett       Date:  2015-11-05       Impact factor: 2.967

6.  Quality-control mechanisms targeting translationally stalled and C-terminally extended poly(GR) associated with ALS/FTD.

Authors:  Shuangxi Li; Zhihao Wu; Ishaq Tantray; Yu Li; Songjie Chen; Jason Dong; Steven Glynn; Hannes Vogel; Michael Snyder; Bingwei Lu
Journal:  Proc Natl Acad Sci U S A       Date:  2020-09-21       Impact factor: 11.205

7.  A phase II open-label study of the intravenous administration of homoharringtonine in the treatment of myelodysplastic syndrome.

Authors:  N Daver; A Vega-Ruiz; H M Kantarjian; Z Estrov; A Ferrajoli; S Kornblau; S Verstovsek; G Garcia-Manero; J E Cortes
Journal:  Eur J Cancer Care (Engl)       Date:  2013-05-23       Impact factor: 2.520

8.  Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin.

Authors:  Junya Kuroda; Yuri Kamitsuji; Shinya Kimura; Eishi Ashihara; Eri Kawata; Yoko Nakagawa; Miki Takeuichi; Yoshihide Murotani; Asumi Yokota; Ruriko Tanaka; Michael Andreeff; Masafumi Taniwaki; Taira Maekawa
Journal:  Int J Hematol       Date:  2008-04-17       Impact factor: 2.490

9.  Homoharringtonine binds to and increases myosin-9 in myeloid leukaemia.

Authors:  Ting Zhang; Shuijie Shen; Zhijuan Zhu; Shasha Lu; Xiufeng Yin; Jiang Zheng; Jie Jin
Journal:  Br J Pharmacol       Date:  2015-12-01       Impact factor: 8.739

10.  Structural basis for the inhibition of the eukaryotic ribosome.

Authors:  Nicolas Garreau de Loubresse; Irina Prokhorova; Wolf Holtkamp; Marina V Rodnina; Gulnara Yusupova; Marat Yusupov
Journal:  Nature       Date:  2014-09-10       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.